key: cord-0971395-ga6v83wp authors: Kanduc, Darja title: From Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Response to Cancer Onset via Molecular Mimicry and Cross-Reactivity date: 2021-09-07 journal: Glob Med Genet DOI: 10.1055/s-0041-1735590 sha: e2a1eb64454b66a430c8716057671b86b46cfa58 doc_id: 971395 cord_uid: ga6v83wp Background and Objectives Whether exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may predispose to the risk of cancer in individuals with no prior cancers is a crucial question that remains unclear. To confirm/refute possible relationships between exposure to the virus and ex novo insurgence of tumors, this study analyzed molecular mimicry and the related cross-reactive potential between SARS-CoV-2 spike glycoprotein (gp) antigen and human tumor-suppressor proteins. Materials and Methods Tumor-associated proteins were retrieved from UniProt database and analyzed for pentapeptide sharing with SARS-CoV-2 spike gp by using publicly available databases. Results An impressively high level of molecular mimicry exists between SARS-CoV-2 spike gp and tumor-associated proteins. Numerically, 294 tumor-suppressor proteins share 308 pentapeptides with the viral antigen. Crucially, the shared peptides have a relevant immunologic potential by repeatedly occurring in experimentally validated epitopes. Such immunologic potential is of further relevancy in that most of the shared peptides are also present in infectious pathogens to which, in general, human population has already been exposed, thus indicating the possibility of immunologic imprint phenomena. Conclusion This article described a vast peptide overlap between SARS-CoV-2 spike gp and tumor-suppressor proteins, and supports autoimmune cross-reactivity as a potential mechanism underlying prospective cancer insurgence following exposure to SARS-CoV-2. Clinically, the findings call for close surveillance of tumor sequelae that possibly could result from the current coronavirus pandemic. From lung damages to skin diseases and excessive immune responses, the disorders associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that is, coronavirus disease 2019 (COVID- 19) , are progressively being defined and diagnostically cataloged. [1] [2] [3] [4] [5] [6] [7] Among the many cancer 13 ; and a higher number of diagnosed head and neck cancers (2.9-8.06% in January-April 2020). 14 Such data have been interpreted as due to the pressure exerted by the viral pandemic on the health care system, so cancer treatments have been delayed and, also, have been related to the viral infection per se. 15 However, how SARS-CoV-2 infection might relate to cancer diseases remains unclear. According to the research paradigm that peptide sequences common to pathogens and the human host may lead to autoimmunity through cross-reactivity, [16] [17] [18] [19] [20] [21] a previous report 22 has proposed cross-reactivity as a likely mechanism that can explain the immunopathology related to SARS-CoV-2 exposure. As a matter of fact, many SARS-CoV-2-derived epitopes were shown to share peptide sequences with human proteins that are involved-when altered, mutated, deficient, and/or improperly functioning-in the etiology of the diseases encompassed by COVID-19. 22 Moreover, and of special importance, it was noted that the viral versus human peptide sharing also involved human proteins related to pleuropulmonary blastoma, non-small cell lung cancer, breast invasive ductal carcinoma, multiple human cancers, tumor predisposition syndrome, and mesothelioma, inter alia. That is, the data suggested the possibility that morbidity/mortality increases in various tumors might represent long-term sequelae following exposure to SARS-CoV-2 (Kanduc 22 and pertinent references therein). Hence, this study was undertaken to further explore the relationship between SARS-CoV-2 infection/active immunization and carcinogenesis, and specifically focused on the amino acid (aa) sequence identities between SARS-CoV-2 spike glycoprotein (gp) and tumor-suppressor human proteins. Analyses revealed a vast peptide sharing potentially able to generate pathogenic autoantibodies via cross-reactivity and immunologic imprinting phenomena, thus possibly leading to or enhancing the onset of a wide spectrum of cancer diseases. Peptide sharing between SARS-CoV-2 spike gp (NCBI, Gen-Bank Protein Accession ID ¼ QHD43416.1) and cancerrelated human proteins was analyzed using pentapeptides as sequence probes as already described. [16] [17] [18] [19] [20] [21] [22] Pentapeptides were used as minimal immune determinant units since a peptide grouping formed of five aa residues defines an immune unit that can (1) induce highly specific antibodies and (2) determine antigen-antibody-specific interaction (Kanduc 23, 24 and further references therein). Seven hundred eighty-two human proteins (in)directly linked to cancer were obtained from UniProtKB database (www.uniprot. org) 25 using "tumor suppressor" as keywords and are listed by UniProt entry in ►Supplementary Table S1 (available in online version only) Methodologically, the spike gp primary sequence was dissected into pentapeptides offset by one residue (i.e., MFVFL, FVFLV, VFLVL, FLVLL, and so forth) and the resulting viral pentapeptides were analyzed for occurrences within the human proteins related to cancer. The shared peptides were also controlled for occurrences in the pathogens Bor-detella pertussis, Corynebacterium diphtheriae, Clostridium tetani, Haemophilus influenzae, and Neisseria meningitides. The publicly available peptide match and peptide search programs (www.uniprot.org) were used. 25 The immunologic potential of the peptides shared between SARS-CoV-2 spike gp and cancer-related proteins was investigated by searching the Immune Epitope Database (IEDB, www.iedb.org) 26 for experimentally validated immunoreactive SARS-CoV-2 spike gp-derived epitopes hosting the shared pentapeptides. Searching UniProt database for tumor-suppressor proteins produced 782 protein entries (in)directly related to tumorsuppressor activity and listed in ►Supplementary Table S1 (available in online version only). Of the 782 proteins, 294 have pentapeptides in common with the spike gp, in a total of 308 occurrences (in all, 462, including multiple occurrences). These numbers certify the existence of an impressive, unexpected level of molecular mimicry between the viral antigen and the cancer-related human proteins. Obvious reasons of space prevent a detailed analysis peptide-by-peptide of the peptide overlap that is given in its entirety in ►Supplementary Table S2 (available in online version only). Here in text, a snapshot of the peptide sharing is reported and discussed. Peptide Sharing between SARS-CoV-2 Spike gp and Tumor-Suppressor Proteins ►Table 1 shows data relative to a representative sample of 19 tumor-suppressor proteins and documents that the peptide commonality with the viral antigen amounts to 29 pentapeptides. From a pathological perspective, ►Table 1 clearly illustrates that even hitting only 19 out of the 294 tumorsuppressor proteins described in ►Supplementary Table S2 (available in online version only) might equate to induce or enhance carcinogenesis in almost all of the human organs, from brain and liver to lung and bones. Examples of the cancers that might be evoked/potentiated by exposure to SARS-CoV-2 in the next future are T cell acute lymphoblastic leukemia, oligodendrogliomas, breast/ovarian cancers, sarcoma, malignant mesothelioma, B cell chronic lymphocytic leukemia, and non-small cell lung carcinoma, among the others. The gloomy outlook hinted at by the findings described in ►Table 1 becomes all the more likely in light of the high immunologic potential of the shared peptides. De facto, investigation of IEDB shows that the 29 pentapeptides shared by the spike gp antigen and the 19 tumor-suppressor proteins (►Table 1) occur and recur in 150 epitopes derived from SARS-CoV-2 that have been experimentally validated and are cataloged as immunoreactive (►Table 2). In essence, ►Table 2 factually supports the possibility that cross-reactions can be triggered by SARS-CoV-2 infection/active immunization and hit human proteins related to carcinogenesis. Very much this conclusion applies when considering that the extent of the potential immunologic cross-reactivity as well as the spectrum of potentially inducible tumors may be exponentially higher in light of the fact that ►Tables 1 and 2 refer to the peptide commonality involving only a tiny part (19 out of 294) of the human proteins that-if altered-may lead to cancer (see ►Supplementary Table S2 [available in online version only] for the peptide sharing in its totality). The 29 pentapeptides common to SARS-CoV-2 spike gp and tumor-suppressor proteins (►Table 1) are not only present in immunoreactive epitopes (►Table 2) but, in addition, almost all of them (24 out of 29) are also present in microbial organisms such as Bordetella pertussis, C. diphtheriae, C. tetani, H. influenzae, and N. meningitides (►Table 3). That is, most of the shared peptides are also present in pathogens that an individual possibly encountered during his life because of infections and/or vaccinal routes. Such interpathogen peptide commonality introduces the immunologic memory as a factor capable of enhancing the extent of the immune cross-reactive response against the tumor-suppressor proteins. That is, as already described since 1947, 48,49 the immune system does not induce ex novo primary responses toward a recent infection. Rather, the immune system recalls, amplifies, and intensifies preexisting memory responses toward past infections. In this way, what should have been a primary response to a recent infection is transformed into an anamnestic, secondary, and magnified response to past infections. Simply put, as already discussed in previous reports, 50-55 the early history of the individual's infections/vaccinations dictates the immune outcomes of any successive infections/vaccinations. The immunologic imprint phenomenon has its molecular foundations in the massive peptide sharing that characterizes microbial and human proteins 17,56,57 and of which ►Table 3 is an example. The implications are noteworthy. In the case object, following exposure to SARS-CoV-2 by infection or vaccination, the expected primary response to the virus can turn into a secondary response to previously encountered pathogens against which the immune system already reacted and of which has stored an immunologic memory, that is, the microbial organisms reported in ►Table 3. However, the previously encountered pathogens are no more present in the human organism, so that the anamnestic immune response triggered by the exposure to SARS-CoV-2 by infection or vaccination ends to divert onto available immune determinants that, in the present case, are the common determinants present in the tumor-suppressor human proteins. Pathologically, one has to consider that usually an anamnestic secondary immune response is characterized by high avidity and high affinity, besides being quantitatively relevant. Therefore, as a final result, exposure to SARS-CoV-2 by infection and/or vaccination can trigger immediate and violent cross-reactive attacks against the proteins that protect the human being from carcinogenesis. The findings described in ►Tables 1 to 3 and ►Supplementary Table S2 (available in online version only) indicate that molecular mimicry and cross-reactivity between peptides common to SARS-CoV-2 and tumor-related proteins might cause/contribute to cancer epidemics worldwide in the next future. The potential cancer risk might be enhanced by immunologic imprinting phenomena, given the fact that the comparative analyses shown in ►Table 3 indicate the possibility that a preexisting immune response to previously encountered pathogens could be magnified and intensified following SARS-CoV-2 infection/active immunization. These data are disturbing and invite to immediately intensify clinical surveillance in oncology and to undertake rigid cancer prevention actions, including healthy lifestyle and continuous controls. It will be vital to formulate/implement actions that contemplate fast and safe procedures for clinical trials, development of specific and reliable tumor markers for diagnosis, accurate follow-up of treatments, and, administratively, medical health records, detailed registries, biobanks, health surveys, and coordinated observational studies. Never before do all the recommendations of the European plan for the fight against cancer appear current and necessary. 58 De facto, tumors appear to be the predominant pathologies that will populate the post pandemic long COVID-19. None. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Skin manifestations as potential symptoms of diffuse vascular injury in critical COVID-19 patients The immune response to SARS-CoV-2 and COVID-19 immunopathology -current perspectives Frequency, signs and symptoms, and criteria adopted for long COVID-19: s systematic review Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infection Systemic and organspecific immune-related manifestations of COVID-19 Implications of low-grade inflammation in SARS-CoV-2 immunopathology COVID-19 and cancer: from basic mechanisms to vaccine development using nanotechnology Commentary: SARS-CoV-2 vaccines and cancer patients Tumor markers as an entry for SARS-CoV-2 infection? Increased hospitalization and mortality from COVID-19 in prostate cancer patients Advanced stages and increased need for adjuvant treatments in breast cancer patients: the effect of the one-year COVID-19 pandemic Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea The impact of coronavirus disease 2019 on head and neck cancer services: a UK tertiary centre study The immuno-oncological challenge of COVID-19 Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences Massive peptide sharing between viral and human proteomes Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins Peptide cross-reactivity: the original sin of vaccines Potential crossreactivity of human immune responses against HCMV glycoprotein B Zika virus and autoimmunity: from microcephaly to Guillain-Barré syndrome, and beyond From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry Pentapeptides as minimal functional units in cell biology and immunology Homology, similarity, and identity in peptide epitope immunodefinition UniProt: a worldwide hub of protein knowledge The Immune Epitope Database (IEDB): 2018 update The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas Structure-function of the tumor suppressor BRCA1 Genetic predisposition to breast and ovarian cancers: how many and which genes to test? DCC (deleted in colorectal carcinoma) gene variants confer increased susceptibility to gallbladder cancer (Ref. No.: Gene-D-12-01446) Rig is a novel Ras-related protein and potential neural tumor suppressor The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties Loss of novel mda-7 splice variant (mda-7s) expression is associated with metastatic melanoma Molecular alterations of h-warts/LATS1 tumor suppressor in human soft tissue sarcoma LATS2 is a tumor suppressor gene of malignant mesothelioma Mutation analysis of the 8p22 candidate tumor suppressor gene ATIP/MTUS1 in hepatocellular carcinoma Identification of DNA methylationregulated differentially-expressed genes and related pathways using Illumina 450K BeadChip and bioinformatic analysis in gastric cancer Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells 3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis SCAI acts as a suppressor of cancer cell invasion through the transcriptional control of beta1-integrin Hyaluronan binding motifs of USP17 and SDS3 exhibit anti-tumor activity Genomic fabric remodeling in metastatic clear cell renal cell carcinoma (ccRCC): a new paradigm and proposal for a personalized gene therapy approach RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia TRIM13 inhibited cell proliferation and induced cell apoptosis by regulating NF-κB pathway in non-small-cell lung carcinoma cells Experience with vaccination against influenza in the spring of 1947: a preliminary report Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus The Guillain-Barrè peptide signatures: from Zika virus to Campylobacter, and beyond Minimal immune determinants connect Zika virus, human cytomegalovirus, and Toxoplasma gondii to microcephaly-related human proteins Immunobiology: on the inexistence of a negative selection process Anti-SARS-CoV-2 Immune response and sudden death: titin as a link Inter-pathogen peptide sharing and the original antigenic sin: solving a paradox Thromboses and hemostasis disorders associated with coronavirus disease 2019: the possible causal role of crossreactivity and immunological imprinting No human protein is exempt from bacterial motifs, not even one The comparative biochemistry of viruses and humans: an evolutionary path towards autoimmunity Europe's Beating Cancer Plan: A new EU approach to prevention, treatment and care The Author(s) None declared.